Calithera Biosciences to Present at the 16th Annual Needham Health Care Conference
March 29, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study
March 28, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
March 27, 2017 16:04 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock
March 22, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
March 20, 2017 16:02 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
March 16, 2017 16:06 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017
March 10, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
March 01, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
February 09, 2017 07:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
January 30, 2017 06:45 ET
|
Calithera Biosciences, Inc.; Incyte Corporation
Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera...